Association of HbA1c with lipid profile in patients with type 2 diabetes mellitus and cardiovascular disease

Volume 5
|
Issue 1
|
Pages 9-
|
2026
3 Views
|
0 Downloads
|
0 Crossref Citations

Abstract

Cardiovascular diseases (CVDs) are major causes of increased mortality and disability across the globe. Effective management of diabetes mellitus (DM) in CVD patients requires the integration of monitoring of glycemic status (HbA1c) and lipid metabolism. This cross-sectional analytical study included 121 patients and 80 control subjects to analyze the association of HbA1c levels with lipid profiles. Serum biochemical analyses of the lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides] were performed with an Agilent 8453 UV‑Visible spectrophotometer (Agilent Technologies, USA), and HbA1c was measured on an A1C EZ 2.0 glycohemoglobin analyzer. Comparisons of characteristics between the groups were performed using chi square or Fisher's exact tests and unpaired Student’s ttests, and the relationships between HbA1c and other variables were determined by correlation and linear regression analyses. The cohort exhibited evidence of poor glycemic control (mean HbA1c of 8.23%) and was associated with increasing age (mean 50.7 years) and weight (mean 70.61 kg). Low levels of HDL-C and a positive family history are associated with disease. Increased age and high body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP) and fasting blood glucose levels were associated with high HbA1c levels (≥ 6.5 %), whereas HDL-C levels were inversely associated with HbA1c. Key correlations included significant positive associations of age, weight, SBP, and DBP with HbA1c (all p < 0.05). HDL-C was negatively correlated with HbA1c (p = 0.04). The association of HbA1c with dyslipidemia confirms interlinked nature of risk factors for CVD and glycemic control. Our findings support integrated clinical management that addresses blood pressure alongside glycemic and lipid targets to help mitigate long-term cardiovascular risk in diabetic patients.

Supplementary materials

The following supporting information can be accessed through the embedded link(s): Supplementary Table/Figure S1. [Table/Figure Caption]; and Supplementary Table/Figure S2. [Table/Figure Caption].

Author contributions

Conceptualization, XX, and YY; methodology, XX; software, XX; validation, XX, YY, and ZZ; formal analysis, XX; investigation, XX; resources, XX; data curation, XX; writing—original draft preparation, XX; writing—review and editing, XX; visualization, XX; supervision, XX; project administration, XX; funding acquisition, YY. All authors have read and agreed to the published version of the manuscript.
The author himself/herself wrote and revised the manuscript.

Publication history

Received Revised Accepted Published
26 April 2026 15 June 2026 20 June 2026 22 June 2026

Funding

Please add: “This research received no specific grant from the public, commercial, or not-for-profit funding agencies.”, “This research was funded by NAME OF FUNDER, grant number XXX” and “The APC was funded by XXX”. Check carefully that the details are accurate and use the standard spelling of funding agency names at https://search.crossref.org/funding.

Data availability

This section provides details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study. Please refer to the suggested Data Availability Statements in the section “Editorial Policies” at https://logixsjournals.com/journals/1/editorial-policy. If the study did not report any data, you might add “Not applicable” here.
The data supporting this study's findings are available from the corresponding author, [Author Name], upon reasonable request.

Acknowledgements

In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support or donations in kind (e.g., materials used for experiments).

Conflicts of interest

Declare conflicts of interest or state, “The author(s) declare(s) no conflicts of interest.” Authors must identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. If there is no role, please state, “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results”.

Publisher's note

Logixs Journals re­mains neutral concerning jurisdic­tional claims in its published subject matter, including maps and institutional affiliations.

Cited by (0)